Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296111 | 0.72 | RAPGEF4 (0.38) | RAPGEF4ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3300242 | 0.71 | TDP1 (0.41) | RAPGEF4ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3296351 | 0.71 | TDP1 (0.41) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| SCHEMBL28951 | 0.69 | RAPGEF4 (0.59) | RAPGEF4ALDH1A1KDM4E | |
| SCHEMBL1551822 | 0.69 | RAPGEF4 (0.59) | RAPGEF4ALDH1A1KDM4E | |
| SCHEMBL3297819 | 0.67 | CYP3A4 (0.33) | — | |
| SCHEMBL3298394 | 0.67 | TRPA1 (0.41) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| SCHEMBL5180888 | 0.67 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4E | |
| SCHEMBL28482658 | 0.67 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4E | |
| SCHEMBL10412763 | 0.67 | RAPGEF4 (0.56) | RAPGEF4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741393-B2 | Organic silicon-based compound and method of producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | ARSA, OR10J3, HDAC10 | RAPGEF4 4702/4885ALDH1A1 1865/4885SMN1; SMN2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.